Phase III Results Position Selecta/Sobi’s SEL-212 As Tough Competition For Krystexxa In Gout

 
• By Alaric DeArment
  
Selecta and Sobi posted positive topline results from their Phase III trials of SEL-212 in chronic refractory gout • Source: Shutterstock

More from Clinical Trials

More from R&D